BioVersys Unveils BV100 Phase 2 Data at IDWeek 2026

BioVersys AG, a clinical stage biopharmaceutical company, has showcased Phase 2 data for its BV100 drug at IDWeek 2026, held in Washington, DC. BV100, an investigational treatment for ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant Acinetobacter baumannii, demonstrated efficacy and safety in 26 patients. These findings were presented in rapid fire and poster sessions by Dr. Andrew F. Shorr from Medstar Washington Hospital Center.

The company is advancing BV100 through Phase 3 trials to offer new treatment options for infections with limited alternatives. Notably, BV100 received US FDA Fast Track Designation, emphasizing its potential in addressing significant healthcare threats posed by drug-resistant bacteria.